Qiagen Stock Price, Forecast & Analysis (NYSE:QGEN)

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen NV (NYSE:QGEN) posted its quarterly earnings results on Wednesday, October, 30th. The company reported $0.36 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.35 by $0.01. The business earned $382.70 million during the quarter, compared to the consensus estimate of $382.98 million. Qiagen had a negative net margin of 1.68% and a positive return on equity of 12.24%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.35 earnings per share. View Qiagen's Earnings History.

Qiagen is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Qiagen.

Qiagen issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion.

14 brokers have issued 12 month price objectives for Qiagen's stock. Their forecasts range from $25.00 to $42.00. On average, they anticipate Qiagen's stock price to reach $33.83 in the next year. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for Qiagen.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 2 sell ratings, 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Qiagen.

Media coverage about QGEN stock has been trending very negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Qiagen earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Qiagen.

Qiagen saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,010,000 shares, an increase of 13.3% from the September 30th total of 3,540,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is currently 2.9 days. Approximately 1.9% of the shares of the company are short sold. View Qiagen's Current Options Chain.

Some companies that are related to Qiagen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), bluebird bio (BLUE), Spark Therapeutics (ONCE), BioNTech (BNTX), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), Twitter (TWTR), NVIDIA (NVDA), Boeing (BA), Activision Blizzard (ATVI), Exelixis (EXEL), Starbucks (SBUX), Booking (BKNG) and Intel (INTC).

Qiagen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (5.55%), Hardman Johnston Global Advisors LLC (1.77%), First Trust Advisors LP (0.68%), Sycomore Asset Management (0.63%), Russell Investments Group Ltd. (0.22%) and Sector Gamma AS (0.21%).

QGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Assenagon Asset Management S.A., Hardman Johnston Global Advisors LLC, Exane Asset Management, Zurcher Kantonalbank Zurich Cantonalbank, Rhumbline Advisers, Crossmark Global Holdings Inc. and First Bank & Trust.

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Massachusetts Financial Services Co. MA, Fisher Asset Management LLC, SG Americas Securities LLC, Sector Gamma AS, Russell Investments Group Ltd., Brinker Capital Inc. and Stephens Investment Management Group LLC.

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of QGEN stock can currently be purchased for approximately $32.26.

Qiagen has a market capitalization of $7.27 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.

The official website for Qiagen is http://www.qiagen.com/.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]